Zealand Pharma's GLP-2 drug candidate fails to gain FDA approval due to request for additional trial to confirm efficacy and safety.

The latest announcement is out from AstraZeneca ( (AZN) ).

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Some tout exosomes as the latest "cure-all"—but alarmed scientists warn we're nowhere near the point when we might ...

Sierra Leone was one of three countries ravaged by the Ebola epidemic 10 years ago. A national vaccine campaign is a big step ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) ...

Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Anavex (AVXL) to $42 from $40 and keeps a Buy rating on the shares ...

The companies decided to withdraw the MAA for Dato-DXd in nonsquamous NSCLC following feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use. Last month, AZN and ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...

The FDA is alerting veterinarians about reports of health problems in dogs, including hundreds of deaths, tied to a drug for ...